Riskpilot← Back to searchSign inGet full accessVivaderm AB
ABActiveOrg 5567711790Kvarntorpsvägen 2 CGeneral medical practice activities · NACE 8621Est. 20082 employees
Revenue 2025
SEK 1,2M
+33% vs 2024
EBITDA margin
22.4%
-10% vs 2024
Equity ratio
64.1%
Financial strength
Net profit 2025
SEK 158K
-22% vs 2024
| Revenue | SEK 1,2M | +33% |
| EBITDA | SEK 275K | -10% |
| Net profit | SEK 158K | -22% |
| Total assets | SEK 3,9M | +32% |
| Equity | SEK 2,5M | +7% |
| Employees | 2 | — |
Legal name
Vivaderm AB
Org number
5567711790
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
28 november 2008
Share capital
SEK 100 000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget ska bedriva medicinsk verksamhet, undervisning, forskning, försäljning av medicinska instrument och därmed förenlig verksamhet. Företaget ämnar även att bedriva konsultativ verksamhet inom hudkirurgi, samt att köpa, sälja och förvalta aktier och värdepapper för eget bruk.
Address
Kvarntorpsvägen 2 C
Email
martha.kallio@hotmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 620 | 1 064 | 905 | 924 | 1 231 |
| Staff expenses | — | −368 | −143 | −92 | −395 |
| EBITDA | 74 | 212 | 150 | 306 | 275 |
| Depreciation & amort. | −73 | −75 | −75 | −52 | −77 |
| EBIT | 1 | 137 | 75 | 254 | 199 |
| Net financials | −1 | −1 | −2 | 1 | −0 |
| Profit before tax | 0 | 136 | 73 | 255 | 199 |
| Tax | −0 | −28 | −15 | −52 | −41 |
| Net profit | 0 | 108 | 58 | 202 | 158 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 2 387 | 3 154 | 2 504 | 2 989 | 3 936 |
| Equity | 1 996 | 2 104 | 2 162 | 2 365 | 2 522 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 391 | 1 049 | 341 | 625 | 1 414 |
| Total debt | 391 | 1 049 | 341 | 625 | 1 414 |
EBITDA margin
22.4%
This company
15.8%
Market median
+42% vs market
20212025
Equity ratio
64.1%
This company
38.2%
Market median
+68% vs market
20212025
Return on equity
6.3%
This company
18.4%
Market median
-66% vs market
20212025
Net profit margin
12.8%
This company
8.1%
Market median
+58% vs market
20212025
Asset turnover
0.31×
This company
1.12×
Market median
-72% vs market
20212025
Debt / equity
0.56×
This company
0.62×
Market median
+10% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2024 | |
| Board of Directors | 2022 | |
| Former (1) | ||
| Deputy Board Member | 2022 – 2024 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Vivaderm AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Mateusz Bloniecki Ziecik | Deputy Board Member | 0 companies |
| Tadeusz Ziecik | Deputy Board Member | 0 companies |
| Margaretha Martha Bloniecka Kallio | Board of Directors | 0 companies |